331 related articles for article (PubMed ID: 37509398)
1. Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.
Molica S; Tam C; Allsup D; Polliack A
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509398
[TBL] [Abstract][Full Text] [Related]
2. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Hatashima A; Karami M; Shadman M
Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
[TBL] [Abstract][Full Text] [Related]
3. Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
Zhou K; Wang T; Pan L; Xu W; Jin J; Zhang W; Hu Y; Hu J; Feng R; Li P; Liu Z; Liu P; Jing H; Gao S; Zhang H; Yu K; Wang Z; Zhu X; Sun Z; Li F; Yan D; Weng J; Fu L; Wang L; Salmi T; Wu K; Qiu L
Ann Hematol; 2024 Jun; ():. PubMed ID: 38888616
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Tam CS; Brown JR; Kahl BS; Ghia P; Giannopoulos K; Jurczak W; Šimkovič M; Shadman M; Österborg A; Laurenti L; Walker P; Opat S; Chan H; Ciepluch H; Greil R; Tani M; Trněný M; Brander DM; Flinn IW; Grosicki S; Verner E; Tedeschi A; Li J; Tian T; Zhou L; Marimpietri C; Paik JC; Cohen A; Huang J; Robak T; Hillmen P
Lancet Oncol; 2022 Aug; 23(8):1031-1043. PubMed ID: 35810754
[TBL] [Abstract][Full Text] [Related]
5. Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions.
Wolska-Washer A; Robak T
Front Oncol; 2023; 13():1130595. PubMed ID: 37035197
[TBL] [Abstract][Full Text] [Related]
6. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
St-Pierre F; Ma S
Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566
[TBL] [Abstract][Full Text] [Related]
7. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
8. Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Alsouqi A; Woyach JA
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38897870
[TBL] [Abstract][Full Text] [Related]
9. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kaźmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang MD; Fu L; Li J; Wu K; Cohen A; Shadman M
N Engl J Med; 2023 Jan; 388(4):319-332. PubMed ID: 36511784
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
Ann Hematol; 2023 Oct; ():. PubMed ID: 37843620
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab.
Ghia P; Barnes G; Yang K; Tam CS; Robak T; Brown JR; Kahl BS; Tian T; Szeto A; Paik JC; Shadman M
Curr Med Res Opin; 2023 Sep; ():1-7. PubMed ID: 37752878
[TBL] [Abstract][Full Text] [Related]
13. Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China.
Gu D; Li J; Miao Y
Expert Opin Pharmacother; 2022 Dec; 23(18):1979-1986. PubMed ID: 36329558
[TBL] [Abstract][Full Text] [Related]
14. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Easaw S; Ezzati S; Coombs CC
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):697-704. PubMed ID: 37544810
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
16. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.
O'Brien SM; Brown JR; Byrd JC; Furman RR; Ghia P; Sharman JP; Wierda WG
Front Oncol; 2021; 11():720704. PubMed ID: 34858810
[TBL] [Abstract][Full Text] [Related]
17. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
Rhodes JM; Mato AR
Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
[TBL] [Abstract][Full Text] [Related]
18. Targeting BTK in CLL: Beyond Ibrutinib.
Bond DA; Woyach JA
Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
[TBL] [Abstract][Full Text] [Related]
19. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
20. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
Paillassa J; Safa F; Troussard X
Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
